Wong, 39,616 patient metformin prophylaxis study: 51% lower mortality [p<0.0001], 41% lower ventilation [p<0.0001], and 40% lower hospitalization [p<0.0001] https://c19p.org/wong2
copied to clipboard
Glycemic Control and Clinical Outcomes in U.S. Patients With COVID-19: Data From the National COVID Cohort Collaborative (N3C) Database
et al., Diabetes Care, doi:10.2337/dc21-2186
N3C retrospective 39,616 COVID-19 patients with diabetes in the USA, showing lower mortality, ventilation, and hospitalization with metformin use.
|
risk of death, 51.0% lower, HR 0.49, p < 0.001, treatment 10,408, control 29,208, Cox proportional hazards.
|
|
risk of mechanical ventilation, 41.0% lower, OR 0.59, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
|
|
risk of hospitalization, 40.0% lower, OR 0.60, p < 0.001, treatment 10,408, control 29,208, adjusted per study, multivariable, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wong et al., 24 Feb 2022, retrospective, USA, peer-reviewed, 15 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.